How many patents does
Pfizer have?
patents
14,186
families
1,145
granted
3,134
applications
11,052
US
2,085
EP
1,113
WO
780
CN
684
JP
598
KR
464
GB
5
RoW
8,457
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Pfizer
Top ten assignees appearing on patents
2009 - 2018
| pfizer | 8970 |
| pfizer products | 1244 |
| amgen fremont | 276 |
| astrazeneca | 244 |
| rinat neuroscience corporation | 221 |
| bristol-myers squibb company | 199 |
| zoetis | 168 |
| wyeth | 164 |
| zoetis services | 142 |
| pharmacia corporation | 118 |
2009
2018
| pfizer | 848 |
| merck patent | 31 |
| zoetis services | 31 |
| amgen fremont | 18 |
| rinat neuroscience corporation | 17 |
| pfizer products | 10 |
| bristol-myers squibb company | 8 |
| codexis | 8 |
| iteos therapeutics | 6 |
| merck & company | 5 |
Pfizer
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| tricyclic compounds and their use as glucocorticoid receptor modulators | 95 | 2007 |
| dispensing device | 89 | 2003 |
| drug loaded polymeric nanoparticles and methods of making and using same | 84 | 2008 |
| triazine compounds as p13 kinase and mtor inhibitors | 80 | 2008 |
| human monoclonal antibodies to activin receptor-like kinase-1 | 74 | 2005 |
| binding molecules to the human ox40 receptor | 70 | 2007 |
| novel adjuvant compositions | 69 | 2008 |
| neisseria meningitidis compositions and methods thereof | 65 | 2012 |
| macrocyclic derivatives for the treatment of proliferative diseases | 64 | 2012 |
| antibodies to insulin-like growth factor i receptor | 64 | 2001 |